Experts and patients from The Myositis Association can speak to the media on Peter Frampton, who has been diagnosed with rare muscle disease inclusion body myositis

 “His message—‘It’s not life threatening, it’s life changing’—is a most powerful antidote for the fear and loss experienced by those of us who live with this disabling condition that has no treatment and no cure," says John McClun, chair of TMA’s Board of Directors and an IBM patient himself.

TMA is the leading international organization committed to the community of people with myositis, their care partners, and family members. The nonprofit provides patient education and advocacy, facilitates patient support groups nationwide, hosts an annual patient conference, engages the medical community in educating physicians about these rare diseases, and funds research into the causes, treatments, and eventual cures for myositis diseases.

TMA Executive Director, Mary McGowan says, “We were excited to learn that Mr. Frampton has started the Peter Frampton Myositis Research Fund at Johns Hopkins, to help raise more money for myositis research. TMA shares this commitment to research. Since 2002, TMA has awarded more than $7 million in myositis researching funding in an effort to better understand this disease, develop more effective therapies, and eventually to discover a cure.”

TMA executive director, Mary McGowan, our Board of Directors, medical advisors, and patients with IBM are available for media interviews.

Journalists are invited to seek additional information about myositis at www.myositis.org. For photos, or to set up an interview with a local patient, myositis medical experts, or TMA’s Executive Director, please call 571-215-7590 or [email protected].